Hims 2025 Sales Outlook Beats Despite Weight-Loss Uncertainty
The company's quarterly sales also beat expectations
Hims' reliance on compounded Ozempic faces increasing scrutiny
By
Save
Hims & Hers Health Inc. provided 2025 sales guidance that exceeded Wall Street projections even as the company's copycat weight-loss drug business faces an unclear future.
Revenue for the year will be $2.3 billion to $2.4 billion, Hims said on Monday afternoon, above analysts' estimates of $2.09 billion.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Hims & Hers Health, Inc. (HIMS) Stock Slides as Market Rises: Facts to Know Before You Trade
Hims & Hers Health, Inc. (HIMS) closed at $55.25 in the latest trading session, marking a -2.83% move from the prior day. This change lagged the S&P 500's 0.55% gain on the day. At the same time, the Dow added 0.25%, and the tech-heavy Nasdaq gained 0.63%. Coming into today, shares of the company had gained 2.99% in the past month. In that same time, the Medical sector gained 3.49%, while the S&P 500 gained 6.29%. Market participants will be closely following the financial results of Hims & Hers Health, Inc. in its upcoming release. The company's upcoming EPS is projected at $0.17, signifying a 183.33% increase compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $551.84 million, up 74.83% from the year-ago period. For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $0.73 per share and a revenue of $2.34 billion, representing changes of +170.37% and +58.31%, respectively, from the prior year. Investors should also take note of any recent adjustments to analyst estimates for Hims & Hers Health, Inc. These revisions help to show the ever-changing nature of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 5.66% upward. Hims & Hers Health, Inc. is currently a Zacks Rank #2 (Buy). From a valuation perspective, Hims & Hers Health, Inc. is currently exchanging hands at a Forward P/E ratio of 77.39. This valuation marks a premium compared to its industry's average Forward P/E of 27.09. Meanwhile, HIMS's PEG ratio is currently 2.12. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical Info Systems industry had an average PEG ratio of 2.12 as trading concluded yesterday. The Medical Info Systems industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 70, which puts it in the top 29% of all 250+ industries. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Keep in mind to rely on to watch all these stock-impacting metrics, and more, in the succeeding trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
McDonald's Shares Slip as GLP-1 Risks Spur Rare Sell Rating
(Bloomberg) -- McDonald's Corp. shares slipped on Tuesday after Redburn Atlantic gave the burger chain its sole sell rating, saying shifting consumer patterns due to weight-loss drugs and inflation are cause for concern. Most Read from Bloomberg Shares of McDonald's fell as much as 1.8% to a March low on the downgrade, a two-notch cut from Redburn's previous buy rating. Redburn held a buy rating on the stock since initiating coverage in 2023. As more Americans turn to GLP-1 drugs like Ozempic to lose weight, McDonald's could see as much as a $428 million annual impact to revenue, representing about 1% of system sales, Redburn Atlantic analysts Chris Luyckx and Edward Lewis wrote. 'A 1% drag today could easily build to 10% or more over time, particularly for brands skewed toward lower-income consumers or group occasions.' The analysts also cut the price target on McDonald's to a Street-low $260, implying a more than 13% decline from where the stock closed on Tuesday. Shares have dropped for seven straight days, their longest losing streak in nearly 12 years, after closing just below a record high in mid-May. Redburn's lowered recommendation was just the latest downgrade for the fast-food giant, which was recently knocked down to hold-equivalent ratings at Morgan Stanley, Loop Capital and Erste Group. Analysts remain largely split on the stock, with 22 buy-equivalent ratings, 18 hold-equivalent ratings and an average price target of $332, according to data compiled by Bloomberg. McDonald's US same-stores sales fell 3.6% in the first-quarter of this year, marking the largest decline since 2020 when people were stuck at home during the pandemic. Fast-food restaurants like McDonald's have also seen a decline in traffic in 40 of the past 43 months, according to the analysts. In addition to the McDonald's call, Redburn also launched coverage of Domino's Pizza Inc. with a sell rating, while starting Chipotle Mexican Grill Inc. as a new neutral. YUM! Brands, Inc., which owns popular brands KFC, Taco Bell and Pizza Hut, was raised to buy from neutral given the stock's 'reasonable' valuation. Despite the slump, McDonald's has increased its average transaction amount through pricing, but lower-income consumers are now opting to eat more at home as the price difference between home and restaurant food increases, according to the report.
Axios
5 hours ago
- Axios
Starbucks taps into health trends with protein coffee test
LAS VEGAS — Starbucks is tapping into the growing demand for protein-packed drinks as consumers seek to boost their intake for health and wellness. Why it matters: The world's largest coffee chain unveiled Tuesday that it is testing protein in its cold foam as part of its "Back to Starbucks" plan. CEO Brian Niccol is trying to reverse a decline in foot traffic and sales by returning to its roots. The big picture: Protein is hot and having a moment beyond social media influencers sharing order hacks. Restaurant brands like Dutch Bros Coffee and Smoothie King have added more protein to their products to cater to changing consumer appetites. Eating a high-protein diet is important to maintain muscle for people taking appetite-suppressing injectable treatments like Ozempic and Wegovy, research shows. Nearly 18 million Americans are expected to be taking versions of GLP-1 drugs by 2029, according to investment bank UBS. Zoom in: Niccol told Axios in an interview Tuesday that the protein cold foam being tested is for a number of different consumer groups including 20-year-old males, 50-year-old females and people taking GLP-1s. "I was watching people coming to our stores, they would get three shots of espresso over ice," Niccol said. "And in some cases, they pull their own protein powder out of their bag, or in other cases, they have a protein drink, like a Fair Life and they'd pour that into their drink." "I'm like, well, wait a second, we can make this experience better for them," he said. "The good news is now I think we're right on trend, and we can do it I think arguably better than anybody else." Flashback: Starbucks had protein smoothies in the past and launched its Vivanno shakes in 2008. They were discontinued in 2018. The company also launched a protein drink in the U.K. last year. The intrigue: Starbucks said the protein powder should be able to be added to any of its cold foam flavors. What's next: Starbucks is testing protein cold foam in five locations in the U.S. under its Starting Five model.
